75% off all plans

JAK-STAT pathway

On this page

JAK-STAT Pathway - Cytokine Superhighway

  • Receptors: Use non-receptor tyrosine kinases (Janus Kinases - JAKs).
  • Ligands: Prolactin, Immunomodulators (e.g., Cytokines, IL-2, IFN), Growth Hormone, Erythropoietin (EPO), Thrombopoietin (TPO). 📌 Mnemonic: "PIGGLET"
  • Function: Essential for hematopoiesis, immune response, and inflammation.

⭐ A gain-of-function mutation in JAK2 (V617F) is a key driver in myeloproliferative neoplasms, especially Polycythemia Vera.

  • Inhibitors: Ruxolitinib (JAK1/2 inhibitor) is used to treat myelofibrosis.

JAK-STAT pathway: cytokine signaling to gene transcription

Key Components - The JAK & STAT Families

  • Janus Kinases (JAKs): Intracellular, non-receptor tyrosine kinases that associate with cytokine receptors. Think of them as the gatekeepers.

    • Four members: JAK1, JAK2, JAK3, & TYK2.
    • They get activated upon receptor-ligand binding.
  • Signal Transducers and Activators of Transcription (STATs): Latent cytoplasmic transcription factors.

    • Seven members: STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b, & STAT6.
    • Function: Once phosphorylated by JAKs, they dimerize, move to the nucleus, and regulate gene transcription.

High-Yield: Mutations in JAK2 (specifically the V617F mutation) are a classic finding in myeloproliferative neoplasms, especially Polycythemia Vera.

JAK-STAT pathway and its biological processes

Regulation - Negative Feedback Loops

  • SOCS (Suppressor of Cytokine Signaling): Key negative regulators. STAT activation induces SOCS gene transcription, creating a feedback loop. SOCS proteins then inhibit JAK activity or target components for proteasomal degradation.
  • PIAS (Protein Inhibitor of Activated STAT): Block STAT DNA-binding activity.
  • PTPs (Protein Tyrosine Phosphatases): E.g., SHP-1; dephosphorylate and inactivate JAKs and STATs.

⭐ In myeloproliferative neoplasms, JAK2 mutations cause constitutive activation, bypassing these negative feedback controls and leading to uncontrolled cell growth.

JAK-STAT pathway negative feedback by SOCS, PIAS, PTPs

Clinical Correlations - Pathologic Signaling

JAK-STAT pathway activation and regulation

  • Gain-of-Function (GOF) Mutations:
    • Constitutively activate JAKs, leading to myeloproliferative neoplasms (MPNs).
    • 📌 Primary myelofibrosis, Vera (polycythemia), Thrombocythemia (essential).
    • Common mutation: JAK2 V617F.
  • Loss-of-Function (LOF) Mutations:
    • Lead to immunodeficiencies by impairing cytokine responses.
    • Example: Autosomal Dominant Hyper-IgE Syndrome (Job Syndrome) from STAT3 mutations → recurrent infections, eczema.
  • Therapeutic Targeting:
    • JAK inhibitors ("-tinibs" e.g., Ruxolitinib, Tofacitinib) treat MPNs and inflammatory conditions like rheumatoid arthritis.

⭐ The JAK2 V617F mutation is present in >95% of patients with polycythemia vera, making it a key diagnostic marker.

High‑Yield Points - ⚡ Biggest Takeaways

  • The JAK-STAT pathway is a primary signaling cascade for cytokines, interferons, and growth factors.
  • It operates via non-receptor tyrosine kinases called Janus kinases (JAKs).
  • Ligand binding causes receptor dimerization, activating JAKs to autophosphorylate and phosphorylate the receptor.
  • STAT proteins are recruited, phosphorylated by JAKs, and then dimerize.
  • These STAT dimers translocate to the nucleus, acting as transcription factors.
  • Dysregulation is central to myeloproliferative neoplasms and many autoimmune diseases.
  • JAK inhibitors (e.g., Ruxolitinib) are crucial targeted therapies.

Continue reading on OnCourse

Sign up for free to access the full lesson, plus unlimited questions, flashcards, AI-powered notes, and more.

CONTINUE READING — FREE

or get the app

Rezzy AI Tutor

Have doubts about this lesson?

Ask Rezzy, our AI tutor, to explain anything you didn't understand

Practice Questions: JAK-STAT pathway

Test your understanding with these related questions

A 2-year-old girl presents to the pediatrician with an itchy rash. Her mother reports that she has had a crusty rash on the face and bilateral upper extremities intermittently for the past 2 months. The child's past medical history is notable for 3 similar episodes of severely itchy rashes since birth. She has also had 2 non-inflamed abscesses on her arms over the past year. Her temperature is 98.9°F (37.2°C), blood pressure is 108/68 mmHg, pulse is 94/min, and respirations are 18/min. On exam, she appears uncomfortable and is constantly itching her face and arms. There is an eczematous rash on the face and bilateral upper extremities. Her face has thickened skin with a wide-set nose. This patient's condition is most likely caused by a mutation in which of the following genes?

1 of 5

Flashcards: JAK-STAT pathway

1/10

Targets of JAK (tyrosine kinase associated-receptor pathway) include _____, which cause transcription of new mRNAs and new protein synthesis

TAP TO REVEAL ANSWER

Targets of JAK (tyrosine kinase associated-receptor pathway) include _____, which cause transcription of new mRNAs and new protein synthesis

STATs

browseSpaceflip

Enjoying this lesson?

Get full access to all lessons, practice questions, and more.

START FOR FREE
Rezzy AI Tutor
JAK-STAT pathway – USMLE Biochemistry Notes | Oncourse